Iqvia Holdings Inc. logo

Iqvia Holdings Inc. (I1QV34)

Market Closed
10 Aug, 19:55
B3 B3
R$
311. 07
+48.24
+18.3541%
R$
175.47B Market Cap
38.04 P/E Ratio
- Div Yield
311 Volume
10.19 Eps
R$ 262.83
Previous Close
Add Transaction
Day Range
302.71 311.07
Year Range
197.21 322.29
Want to track I1QV34 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Upcoming I1QV34 split of 4:1 in 14 days (24 Aug 2026)

Summary

I1QV34 closed today higher at R$311.07, an increase of 18.3541% from yesterday's close, completing a monthly increase of 38.2902% or R$86.13. Over the past 12 months, I1QV34 stock gained 1.4612%.
I1QV34 is not paying dividends to its shareholders.
The last earnings report, released on May 04, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Iqvia Holdings Inc. has a scheduled stock split on Aug 24, 2026 for a 4:1 split ratio, meaning every I1QV34 investor will receive 4.0 shares for every 1.0 existing shares.
Iqvia Holdings Inc. has completed 2 stock splits, with the recent split occurring on Jul 30, 2026.
The company's stock is traded on one exchange.

I1QV34 Chart

People also search for

Weg S.A.
R$ 47.63
-1.0183%
Agilent Technologies Inc.
R$ 72.26
0%
Waters Corporation
R$ 476.58
0%
Roper Technologies Inc.
R$ 200.23
0%
WEG S.A.
R$ 47.54
-1.1026%

Iqvia Holdings Inc. (I1QV34) FAQ

What is the stock price today?

The current price is R$311.07.

On which exchange is it traded?

Iqvia Holdings Inc. is listed on B3.

What is its stock symbol?

The ticker symbol is I1QV34.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 175.47B.

Has Iqvia Holdings Inc. ever had a stock split?

Iqvia Holdings Inc. had 2 splits and the recent split was on Jul 30, 2026.

Iqvia Holdings Inc. Profile

Professional Services Industry
Industrials Sector
Ari Bousbib CEO
B3 Exchange
- ISIN
US Country
93,000 Employees
- Last Dividend
24 Aug 2026 Last Split
9 May 2013 IPO Date

Overview

IQVIA Holdings Inc. is a cutting-edge company providing a suite of analytics, technology solutions, and clinical research services tailored for the life sciences sector. Operating globally, including the Americas, Europe, Africa, and the Asia-Pacific regions, IQVIA stands at the forefront of facilitating healthcare advancements. The company is organized into three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, catering to a diverse range of needs within the pharmaceutical, biotechnology, medical device and diagnostic, and consumer health industries. Originally known as Quintiles IMS Holdings, Inc., it underwent a rebranding to IQVIA Holdings Inc. in November 2017. With its headquarters in Durham, North Carolina, IQVIA continues to foster collaborations, including a notable partnership with argenx SE, to drive innovation and improve patient outcomes in healthcare.

Products and Services

  • Technology & Analytics Solutions
  • This segment offers a plethora of cloud-based applications coupled with implementation services designed explicitly for life sciences and healthcare providers. It helps in generating real-world evidence for healthcare decision-making and enhancing patient outcomes. Among these services are strategic and implementation consulting, encompassing advanced analytics and commercial processes outsourcing. Moreover, IQVIA provides critical metrics related to pharmaceutical sales, prescribing trends, medical treatments, and various promotional activities, not to mention detailed sales or prescribing data at different geographical levels.

  • Research & Development Solutions
  • This division supports the full spectrum of clinical trial and research development, including project management, clinical monitoring, and patient-centric solutions. It assists in strategic planning and design for clinical trials, central laboratory services, genomic, bioanalytical, ADME (Absorption, Distribution, Metabolism, and Excretion), discovery, and vaccine and biomarker laboratory services, thereby accelerating the journey from early-stage research to market-ready products.

  • Contract Sales & Medical Solutions
  • Focused on enhancing engagement with healthcare providers and patients, this segment delivers comprehensive services spanning from health care provider engagement to scientific strategy and medical affairs. These solutions aim to optimize interactions between the medical community and the industry to foster a deeper understanding and adoption of advanced healthcare solutions and treatments.

Contact Information

Address: 2400 Ellis Road
Phone: 919 998 2000